Valeant Pharmaceuticals International, Inc. (VRX) Lowered to Hold at Vetr Inc.

Vetr cut shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) from a strong-buy rating to a hold rating in a research report sent to investors on Friday morning. They currently have $14.26 price objective on the specialty pharmaceutical company’s stock.

VRX has been the subject of a number of other research reports. J P Morgan Chase & Co set a $10.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a hold rating in a research report on Monday, July 17th. HC Wainwright restated a hold rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a buy rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a buy rating and a $18.00 target price for the company. Finally, Wells Fargo & Company reiterated an underperform rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $17.71.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 12.92 on Friday. The firm’s market capitalization is $4.50 billion. The company has a 50 day moving average price of $13.96 and a 200-day moving average price of $13.57. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.88) EPS. On average, equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/17/valeant-pharmaceuticals-international-inc-vrx-lowered-to-hold-at-vetr-inc.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.87% of the company’s stock.

Large investors have recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Valeant Pharmaceuticals International by 2.9% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock worth $8,509,000 after purchasing an additional 13,810 shares during the period. Morgan Stanley lifted its holdings in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the period. Legal & General Group Plc lifted its holdings in Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after buying an additional 121,032 shares during the period. Paloma Partners Management Co lifted its holdings in Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after buying an additional 2,996 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Valeant Pharmaceuticals International in the first quarter value

VRX has been the subject of a number of other research reports. J P Morgan Chase & Co set a $10.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a hold rating in a research report on Monday, July 17th. HC Wainwright restated a hold rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a buy rating and set a $23.00 target price on shares of Valeant Pharmaceuticals International in a report on Tuesday, August 29th. Guggenheim assumed coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They set a buy rating and a $18.00 target price for the company. Finally, Wells Fargo & Company reiterated an underperform rating and set a $9.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $17.71.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 12.92 on Friday. The firm’s market capitalization is $4.50 billion. The company has a 50 day moving average price of $13.96 and a 200-day moving average price of $13.57. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.88) EPS. On average, equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/17/valeant-pharmaceuticals-international-inc-vrx-lowered-to-hold-at-vetr-inc.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.87% of the company’s stock.

Large investors have recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Valeant Pharmaceuticals International by 2.9% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 490,395 shares of the specialty pharmaceutical company’s stock worth $8,509,000 after purchasing an additional 13,810 shares during the period. Morgan Stanley lifted its holdings in Valeant Pharmaceuticals International by 48.2% in the first quarter. Morgan Stanley now owns 2,777,063 shares of the specialty pharmaceutical company’s stock valued at $30,631,000 after buying an additional 903,256 shares during the period. Legal & General Group Plc lifted its holdings in Valeant Pharmaceuticals International by 9.2% in the second quarter. Legal & General Group Plc now owns 1,435,670 shares of the specialty pharmaceutical company’s stock valued at $23,895,000 after buying an additional 121,032 shares during the period. Paloma Partners Management Co lifted its holdings in Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after buying an additional 2,996 shares during the period. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Valeant Pharmaceuticals International in the first quarter valued at $513,000. Institutional investors own 50.44% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply